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b-Site amyloid precursor protein cleaving enzyme-1 (BACE1) is a central molecule in Alzheimer’s dis-
ease (AD). It cleaves amyloid precursor protein (APP) to produce the toxic amyloid-b (Ab) peptides.
Thus, a novel BACE1 modulator could offer a new therapeutic strategy for AD. We report that C-type
lectin-like domain family 4, member g (Clec4g, also designated as LSECtin) interacts with BACE1 in
mouse brain and cultured cells. Overexpression of Clec4g suppressed BACE1-mediated Ab genera-
tion, and affected the intracellular distribution of BACE1 but not its catalytic activity. These results
highlight a novel role of Clec4g in negatively regulating BACE1 function.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction cognitive function [10]. Furthermore, loss of bisecting GlcNAc didAlzheimer’s disease (AD) is the most common form of dementia
and a serious issue worldwide [1]. The emergence of senile plaques
consisting of amyloid-b (Ab) peptide in the brain is one of the hall-
marks of AD [2], and the accumulation of Ab peptide is considered
to be the central event for AD development [3]. Ab peptide is gen-
erated by the two-step proteolysis of amyloid precursor protein
(APP) [4]. b-Site amyloid precursor protein cleaving enzyme-1
(BACE1) is responsible for the ﬁrst APP cleavage and is a promising
drug target for AD [5]. However, the fact that Bace1-deﬁcient mice
show severe phenotypes, including lethality, hypomyelination and
muscle abnormality [6–8] led to the concern that BACE1 inhibitors
could cause severe side effects.
We recently found that a unique sugar modiﬁcation ‘‘bisecting
GlcNAc’’ [9] is selectively attached to BACE1 and that the loss of
this glycan relocates BACE1 from early endosomes to late endo-
somes/lysosomes, leading to reduced Ab generation and improvednot impair or barely impaired the cleavage of other BACE1 sub-
strates, suggesting that the post-translational sugar modiﬁcation
of BACE1 could be a novel drug target with fewer side effects.
Although some other molecules such as Vps35 and GGA3 were also
reported to be involved in the regulation of BACE1 subcellular
localization [11,12], the detailed mechanisms of how BACE1 func-
tion and distribution are regulated in cells are not fully understood.
In particular, it remains unclear how glycans on BACE1 act in cells
to regulate its subcellular localization, and what molecule recog-
nizes BACE1 glycans. Therefore, identiﬁcation of a new BACE1
modulator having glycan-binding activity could promote our
understanding of BACE1 biology, leading to the discovery of a
new drug target for AD.
In this study, we identiﬁed a novel BACE1-interacting lectin,
C-type lectin-like domain family 4, member g (Clec4g), and found
that this lectin suppressed BACE1 function by affecting the subcel-
lular localization of BACE1. These data suggest that regulation of
Clec4g represents a novel approach to modulate BACE1 function.
2. Materials and methods
2.1. Antibodies
The following commercially available antibodies were used:
rabbit anti-BACE1 (5606), and rabbit anti-rab5 (3547) from Cell
Signaling Technology; mouse anti-myc (clone 9E10) (BML
Fig. 1. Identiﬁcation of a novel BACE1-interacting lectin, Clec4g. (A) BACE1 was extracted and immunoprecipitated from amembrane fraction of 1-week-old mouse brain. The
immunoprecipitate was subjected to SDS–PAGE and silver staining. The arrow indicates a band excised from the gel. (B) Neuro2A cells were transfected with plasmids
encoding human BACE1 and/or mouse Clec4g-myc, or with empty plasmid. Cells were lysed, and BACE1 or Clec4g-myc was immunoprecipitated. The cell lysates (left), and
the immunoprecipitates (middle and right) were then blotted with an anti-BACE1 antibody or anti-myc antibody.
Fig. 2. Knockdown of GnT-III does not affect BACE1–Clec4g interaction. (A)
Neuro2A cells were transfected with control siRNA or siRNA for GnT-III (encoded
byMgat3), and then the expression levels ofMgat3mRNA relative to those of Gapdh
were quantiﬁed using realtime PCR (n = 3). Cell lysates after siRNA transfection
were blotted with E4-PHA lectin or anti-actin antibody. (B) Neuro2A cells were
transfected with plasmids encoding mouse Clec4g-myc or with an empty plasmid.
After 24 h, cells were replated, and then transfected with control siRNA or siRNA for
GnT-III (Mgat3). Cells were lysed, and Clec4g-myc was immunoprecipitated. The
cell lysates (left), and the immunoprecipitates (right) were then blotted with an
anti-BACE1 antibody or anti-myc antibody.
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Sigma; rabbit anti-sAPPb (18957) and rabbit anti-APP C-terminal
region from Immuno-Biological Laboratories; anti-APP
N-terminal region (clone 22C11) (MAB348) from Millipore;
anti-O-GlcNAc transferase (OGT) (sc-32921) from Santa Cruz
Biotechnology; mouse anti-EEA1 (610457), mouse anti-Adaptin-c
(610386) and mouse anti-PDI (610946) from BD Biosciences.
Biotinylated erythroagglutinating phytohemagglutinin (E4-PHA)
lectin was from Seikagaku Corporation.2.2. Identiﬁcation of Clec4g by LC–MS
Brains from C57BL/6 mice were homogenized in a buffer con-
taining 20 mM Tris–HCl pH 7.6, 150 mM NaCl, and protease inhibi-
tors. After removal of nuclei and cell debris by centrifugation at
500g for 10 min, the supernatant was ultracentrifuged at
105000g for 20 min. The resultant pellet (the membrane frac-
tion) was suspended in a buffer containing 20 mM Tris–HCl pH
7.6, 150 mM NaCl, 0.5% Nonidet P-40, and protease inhibitors, then
subjected to sonication and incubated on ice for 15 min. After
ultracentrifugation at 105000g for 20 min, the cleared lysate
was subjected to immunoprecipitation using an anti-BACE1 anti-
body as described below. The immunoprecipitate was subjected
to SDS–PAGE and silver staining. Bands around 25kDa except IgG
light chain were excised and cut into small pieces. After washing
and destaining the gel, cystines were reduced by dithiothreitol
and alkylated with iodoacetamide. The proteins were digested
with modiﬁed trypsin, and the resulting peptides were subjected
to LC–MS/MS. LC–MS/MS analysis was performed using Advance
nanoLC (Bruker-Michrom) and LTQ linear ion trap mass spectrom-
eter (Thermo Fisher Scientiﬁc) equipped with a nanospray ion
source. The peptides were separated using an InertSustain C18 col-
umn (0.1  150 mm, 3 lm, GL Science) and a linear gradient
(60 min, 5–65% CH3CN/0.1% formic acid) at a ﬂow rate of
500 nl/min. The resulting MS and MS/MS data were searched
against the Swiss-Prot database using MASCOT software (Matrix
Science). LC–MS/MS analysis was performed with the help of the
Support Unit for Bio-Material Analysis in the RIKEN BSI Research
Resources Center. All animal experiments were approved by the
Animal Experiment Committee of RIKEN.
2.3. SDS–PAGE, silver staining, western blot and lectin blot
These experiments were carried out as described previously
[10]. Silver staining was performed using the Silver Stain MS Kit
(Wako) according to the manufacturer’s protocol.
2.4. RNA extraction, reverse-transcription and realtime PCR
These experiments were performed as described previously
[10].
2.5. Plasmids
The methods for construction of the expression plasmid for
full-length human BACE1 were described previously [13]. Mouse
Clec4g cDNAwas ampliﬁed from amouse liver cDNA library, which
Fig. 3. APP cleavage by BACE1 is suppressed by expression of Clec4g. (A) Neuro2A cells were transfected with plasmids encoding human BACE1 and/or mouse Clec4g-myc or
with an empty plasmid. Cells were lysed and Western blotted for Clec4g-myc and BACE1 (left). Proteins secreted into the culture media were ethanol precipitated and
Western blotted for sAPPb and total sAPP (stained with 22C11 mAb) (right). (B) Neuro2A cells were transfected with a plasmid encoding mouse Clec4g-myc or with an empty
plasmid, and then the amount of Ab40 in the culture medium was measured (n = 3). The graph shows means ± S.E.M. (⁄⁄P < 0.01, Student’s t-test).
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Technologies) of total RNA from C57BL/6 mouse liver, using the
primers GTGGAATTCACCACCATGAACACTGGTGA and GCTTAGTA
GCAACTGCTCCTCTTCT, and the product was ligated into the
pCR-Blunt plasmid (Life Technologies). For the construction of
Clec4g-myc (tagged with myc and 6 His at its C-terminus) plas-
mid, the full-length mouse Clec4g cDNA, skipping its stop codon,
was ampliﬁed by PCR with the primers GTGGAATTCACCACCATG
AACACTGGTGA and CTACTCGAGGTAGCAACTGCTCCTCTTC, and
the product was ligated into the pCDNA6/myc-His A plasmid using
EcoRI and XhoI sites.
2.6. Cell culture, transfection, siRNA treatment and
immunoprecipitation
Neuro2A cells were cultured in DMEM supplemented with 10%
FBS and subjected to plasmid or siRNA transfection as described
previously [10]. siRNA for mouse Mgat3 was purchased from
Qiagen (SI01304590). Immunoprecipitation was performed as
described [10] with a slight modiﬁcation. Dynabeads protein G
(Life Technologies) was used instead of protein G-Sepharose 4
Fast Flow. Immunoprecipitation was performed in the presence
of 1 mM CaCl2. Western blotting of secreted proteins was per-
formed after ethanol precipitation as described [14].
2.7. Ab ELISA, b-secretase assay and sucrose density gradient
fractionation
These experiments were carried out as described previously
[10] with slight modiﬁcations. Ab ELISA was performed using the
culture media after centrifugation (10000g for 1 min) and subse-
quent threefold dilution with PBS. For the b-secretase assay, the
cells were lysed with a buffer containing 20 mM Tris–HCl, pH
7.6, 150 mM NaCl, 1 mM CaCl2, 0.5% Nonidet P-40, and protease
inhibitors. After centrifugation at 15000g for 20 min, the super-
natant was used as an enzyme source. The protein concentrations
in the lysates were measured using a Pierce BCA Protein assay kit
(Thermo Fisher Scientiﬁc). The ﬂuorogenic substrate peptide for
BACE1 was purchased from R&D Systems (ES004).
3. Results
3.1. Clec4g is a novel BACE1-interacting protein
Our recent report showed that the glycans on BACE1 critically
regulate BACE1-mediated Ab generation by controlling thetrafﬁcking of BACE1 to lysosomes [10], suggesting the presence
of a molecule that interacts with BACE1 in a glycan-dependent
manner and regulates the intracellular localization of BACE1. To
identify such a novel BACE1 modulator, we ﬁrst puriﬁed BACE1
by immunoprecipitation from 1-week-old mouse brains (Fig. 1A),
and analyzed the co-puriﬁed protein by in-gel digestion and LC–
MS. In an excised gel piece containing proteins from 20kDa to
25kDa (Fig. 1A, arrow), one protein, Clec4g (LSECtin), not previ-
ously reported as a BACE1-interactor, was identiﬁed (a peptide,
K. DIQAK. L, was identiﬁed). Clec4g is a lectin homologous to den-
dritic cell-speciﬁc intracellular adhesion molecule-3-grabbing
non-integrin (DC-SIGN) and DC-SIGN-related protein (DC-SIGN-R)
[15,16]. Clec4g was reported to be involved in virus entry
[17,18], but has not been reported to be associated with AD
pathogenesis.
To clarify a possible novel mechanism underlying AD develop-
ment and new therapeutic target, we further investigated the bio-
logical role of the interaction between Clec4g and BACE1. We ﬁrst
conﬁrmed the interaction in cultured cells. BACE1 and myc-tagged
Clec4g were overexpressed in Neuro2A cells, and then these pro-
teins were immunoprecipitated. Clec4g-myc was detected in the
immunoprecipitate using anti-BACE1 antibody (Fig. 1B lower mid-
dle, lane 4). This signal was not detected without BACE1 expression
(Fig. 1B lower middle, lane 2), conﬁrming the speciﬁc interaction of
these two proteins. Likewise, BACE1 was detected in the immuno-
precipitate using anti-myc antibody when Clec4g-myc was
co-expressed (Fig. 1B upper right, lane 4). These data indicate that
BACE1 interacts with Clec4g in living cells.
As Clec4g is a glycan-binding lectin, we next investigated
whether the interaction between BACE1 and Clec4g is mediated
by a speciﬁc glycan on BACE1. As we previously revealed that
BACE1 is selectively modiﬁed with bisecting GlcNAc and that
this modiﬁcation critically regulates intracellular trafﬁcking of
BACE1 [10], we hypothesized that the interaction between
BACE1 and Clec4g might be mediated by bisecting GlcNAc on
BACE1. Knockdown of GnT-III (encoded by Mgat3 gene), a
biosynthetic enzyme for bisecting GlcNAc [9], in Neuro2A cells
resulted in decrease in the level of bisecting GlcNAc, which
was conﬁrmed by reduced reactivity with a bisecting
GlcNAc-binding lectin, E4-PHA (Fig. 2A). However, the interac-
tion between endogenous BACE1 and expressed Clec4g was
not inﬂuenced by GnT-III knockdown (Fig. 2B, upper right, com-
pare lane 3 and 4). These data indicate that bisecting GlcNAc on
BACE1 is unlikely involved in this interaction and that these
two proteins probably bind through other glycans or a polypep-
tide moiety of BACE1.
Fig. 4. Clec4g regulates the subcellular distribution of BACE1. (A) Neuro2A cells were transfected with plasmids encoding human BACE1 and/or mouse Clec4g-myc or with an
empty plasmid. Cells were lysed, and then the lysates were subjected to in vitro b-secretase assay (left graph) (n = 3). The same lysates wereWestern blotted with anti-BACE1,
anti-myc, and anti-O-GlcNAc transferase (OGT) antibodies. OGT was examined as a loading control. (B) Neuro2A cells were transfected singly with a plasmid encoding human
BACE1 or doubly with plasmids encoding human BACE1 and mouse Clec4g-myc. Cell homogenates were fractionated by sucrose density gradient centrifugation and Western
blotted with anti-BACE1, anti-APP (raised against C-terminal region), and anti-myc antibodies. Signal intensities relative to those in total fractions were quantiﬁed and are
shown in the graphs on the right (n = 3). A non-speciﬁc band in lane 2 in the anti-myc blots was excluded from the quantiﬁcation. In the case of BACE1 single transfectant,
signal intensities in the myc blot are shown as relative values to the total intensity of the myc blot from the double transfectant because of the weak signal in the BACE1 single
transfectant. (C) Neuro2A cells were doubly transfected with plasmids encoding human BACE1 and mouse Clec4g-myc. Cell homogenates were fractionated by sucrose
density gradient centrifugation and Western blotted with anti-EEA1, anti-Rab5, anti-Adaptin-c, and anti-PDI antibodies. All graphs show means ± S.E.M.
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BACE1 cleaves APP to generate two fragments, the N-terminal
fragment sAPPb and the C-terminal fragment CTFb [19]. sAPPb is
secreted into culture medium, and CTFb is subsequently cleaved
by c-secretase to generate Ab that is also secreted [20]. To examine
the effect of the BACE1–Clec4g interaction on b-site cleavage of
APP by BACE1 in cells, we next analyzed the amount of BACE1
products in culture media. We overexpressed BACE1 in Neuro2A
cells with or without Clec4g. BACE1 overexpression led to an
increase in sAPPb levels in culture medium (Fig. 3A, upper right,
lane 3), while such an increase was largely inhibited by
co-expression with Clec4g (Fig. 3A, upper right, lane 4).Furthermore, the amount of Ab40, a major Ab species, in the cul-
ture media, was also decreased by overexpression of Clec4g
(Fig. 3B). These results indicate that Clec4g suppresses APP cleav-
age by BACE1, leading to reduced Ab production.
3.3. Clec4g regulates the subcellular localization of BACE1
We next examined how BACE1 function was suppressed by
Clec4g. First, we measured the catalytic activity of BACE1 in vitro
towards an APP-derived FRET peptide substrate using lysates of
cells overexpressing BACE1 and/or Clec4g (Fig. 4A, right panels).
By overexpressing BACE1, a large increase in ﬂuorescence signal
was observed (Fig. 3A, graph), conﬁrming that this assay surely
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activity was not inhibited by co-expression of Clec4g (Fig. 4A).
These data suggest that expressed Clec4g did not interfere with
the catalytic activity of BACE1.
Next, we focused on the subcellular localization of BACE1,
because an endosomal localization of BACE1 was reported to be
critical to APP cleavage [10,11,21]. BACE1 was fractionated into
two broader peaks (fractions 2–5 and 7–11) by sucrose density
gradient fractionation of Neuro2A cell homogenates (Fig. 4B).
When Clec4g was co-expressed, a shift in BACE1 distribution was
found from the lighter fractions (fractions 2–5) to the heavier frac-
tions (fraction 7–11), where Clec4g was mainly distributed. By
contrast, APP distribution, which was observed mainly in fraction
7–11 and weakly in fraction 2–5, was not affected by Clec4g over-
expression. Western blotting for organelle markers showed that
markers for early endosome, that is considered to be a major
Ab-generating organelle [10], were mainly distributed in fraction
2, while Golgi and ER markers were more broadly distributed in
heavier fractions (fractions 7–11) as well as in the lighter fractions
(fractions 2–5) (Fig. 4C). Considering these results and previous
results showing that Clec4g overexpression reduced Ab generation
(Fig. 3), it is suggested that Clec4g likely relocated BACE1 from
early endosomes to Golgi or ER where Ab is unlikely generated.
Collectively, these data suggest that Clec4g regulates BACE1 local-
ization, but not its catalytic activity, thereby suppressing
BACE1-mediated APP cleavage.
4. Discussion
In this study, for the ﬁrst time, we revealed that a C-type lectin,
Clec4g, is a novel suppressor of BACE1 function. Clec4g was
reported to have a lectin activity different from its homologs
DC-SIGN and DC-SIGNR, and to preferentially bind to non-sialyl
N-glycans without bisecting GlcNAc in a calcium-dependent man-
ner [16]. Clec4g was ﬁrst reported to have an afﬁnity for monosac-
charides (mannose, GlcNAc, and fucose) [15]. A detailed analysis
using glycan array and inhibition assays subsequently demon-
strated that a terminal GlcNAcb1-2Man disaccharide is likely the
most preferred ligand for Clec4g [17]. Our knockdown experiments
(Fig. 2) suggest that bisecting GlcNAc is unlikely involved in the
BACE1–Clec4g interaction, and it will be important in a future
study to determine whether the BACE1–Clec4g interaction is medi-
ated by BACE1 N-glycans or its polypeptide component.
Clec4g was reported to be highly expressed in endothelial cells
rather than neurons [15]. Although neurons are considered to play
central roles in the production and deposition of Ab, vascular fac-
tors also make a considerable contribution to AD pathogenesis
[22]. In AD brain, Ab deposition is observed in blood vessels as well
as in the brain parenchyma [23], and endothelial cells themselves
actually express APP and BACE1 to produce Ab peptide [24]. These
data suggest that the Clec4g–BACE1 interaction could play some
roles in the prevention of Ab production in endothelial cells, rather
than in neurons, through the regulation of BACE1 localization.
From a therapeutic point of view, BACE1 inhibitors are now in
clinical trials, but there are some concerns regarding side effects.
It would be desirable to suppress BACE1-mediated Ab generation
without affecting the physiologically indispensable functions of
BACE1, such as cleavage of neuregulins [4]. Regulation of a
BACE1 modulator such as Clec4g could be an alternative means
of reducing Ab generation in AD therapy.Acknowledgements
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